Inhibition of TIM-3 using an anti-TIM-3 mAb increased the secretion of CXCL9 by the CD103+ DCs, which led to an increased infiltration and activation of CTLs into MMTV-PyMT tumours, thereby improving the therapeutic activity of chemotherapeutic agent paclitaxel (Figure 1F) [84]. The gene discussed is HAVCR2; the disease is neoplasm.